Biomolecules and Biomedicine is a pioneering open-access journal dedicated to advancing the fields of molecular biology and biomedical sciences, published by the Association of Basic Medical Science Federation Bosnia & Herzegovina in Sarajevo. With the ISSN 2831-0896 and the E-ISSN 2831-090X, this journal aims to facilitate the dissemination of high-quality research from 2023 onwards, inviting submissions that provide innovative insights and findings across various facets of medicine and biological sciences. Positioned within the General Medicine and Biochemistry, Genetics and Molecular Biology categories, it currently holds rankings of 332 out of 636 and 173 out of 221 respectively, highlighting its emerging influence in these fields. As an open-access journal, it ensures that all published research is freely accessible to a global audience, fostering collaboration and knowledge exchange among researchers, professionals, and students alike. With a commitment to enhancing scientific discourse and promoting cutting-edge research, Biomolecules and Biomedicine is poised to become a vital resource for those dedicated to unraveling the complexities of biomolecules and their roles in health and disease.

BioMedicine-Taiwan, published by DIGITAL COMMONS BEPRESS, stands as a prominent open-access journal that has been disseminating vital research since 2014. With an ISSN of 2211-8020 and E-ISSN 2211-8039, this journal covers a wide array of disciplines within the biomedical field, reaching researchers and professionals keen on exploring cutting-edge advancements and innovative approaches in biochemistry, genetics, and general medicine. Notably categorized as Q2 in Biochemistry, Genetics and Molecular Biology and Q3 in Medicine for 2023, BioMedicine-Taiwan ranks well in its respective fields, reflecting its commitment to enhancing scholarly communication and knowledge dissemination. Situated in Taiwan, its impact is further highlighted by its Scopus rankings—placing it in the 70th percentile for general medicine and 47th percentile for general biochemistry and molecular biology, showcasing its significance in ongoing biomedical discourse. Researchers, students, and professionals are invited to engage with this invaluable resource to explore the latest findings and developments that shape the future of healthcare and biological sciences.

EMBO Molecular Medicine, published by WILEY, stands as a premier forum within the field of molecular medicine, advancing scholarly dialogue and research since its launch in 2009. With an impressive impact factor reflected in its Q1 categorization and ranking as the 12th journal in the discipline of Molecular Medicine by Scopus, it serves as a vital resource for researchers, professionals, and students alike. Operating under an Open Access model, EMBO Molecular Medicine ensures that cutting-edge research is freely accessible, fostering greater collaboration and innovation among the global scientific community. Located in the United Kingdom, the journal encompasses a broad scope, featuring high-quality studies that bridge the gaps between basic molecular biology and clinical applications, making significant impacts on health and disease. With a commitment to excellence and a continuously evolving repertoire of research, this journal play a crucial role in shaping the future of biomedical research and therapy.

Open Medicine, with ISSN 2391-5463 and E-ISSN 2391-5463, is a distinguished peer-reviewed journal published by De Gruyter Poland Sp. z o.o, focusing on a broad array of topics in the field of medicine. Since its inception in 2013, the journal has maintained an Open Access policy, fostering the dissemination of scientific knowledge across global audiences and promoting collaborative research efforts. Based in Germany, Open Medicine has established itself within the medical community, achieving a respectable Q3 ranking in the category of Medicine (Miscellaneous) as of 2023, and placing in the 72nd percentile in general medicine according to Scopus rankings. The journal aims to bridge gaps in research by offering a platform for innovative studies, clinical trials, and comprehensive reviews that advance medical knowledge and practice. With a commitment to enhancing accessibility and visibility of research, Open Medicine plays a vital role in encouraging the continued development of the medical field, making it an essential resource for researchers, professionals, and students alike.

Welcome to Advances in Clinical and Experimental Medicine, an esteemed publication by WROCLAW MEDICAL UNIVERSITY, dedicated to advancing the essential fields of clinical and experimental medicine. With an open access model since 2017, this journal ensures that researchers, healthcare professionals, and students worldwide can freely access high-quality scientific content. Covering a broad spectrum of topics including biochemistry, genetics, internal medicine, and pharmacology, Advances in Clinical and Experimental Medicine has established itself as a pivotal resource in the scientific community, currently holding prestigious rankings such as Q2 in Biochemistry, Genetics, and Molecular Biology (miscellaneous) and Q1 in Reviews and References (medical) for 2023. Spanning over two decades of rigorous research publication, the journal is a critical platform for sharing innovative findings and fostering collaboration among scholars, making it an invaluable asset for those at the forefront of medical science.

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

Biomed Research International is a prominent open access journal published by HINDAWI LTD, dedicated to advancing the field of biomedical research. With its ISSN 2314-6133 and E-ISSN 2314-6141, this journal has been a significant contributor to the scientific community since its inception in 2013, making scholarly work accessible to a global audience. The journal's scope encompasses a range of disciplines, including biochemistry, genetics, molecular biology, immunology, microbiology, and medicine, reflecting its commitment to interdisciplinary research. Ranked in the Q2 quartile as of 2023 across several relevant categories, Biomed Research International is recognized for its high-quality publications that foster innovation and collaboration in biomedical studies. Researchers, professionals, and students looking to share and gain insights into cutting-edge biomedical discoveries will find this journal an essential resource. With a focus on rapid dissemination of research findings, the journal serves as a vital platform for academics to engage with contemporary issues in health and disease, ultimately contributing to the advancement of medical science.

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.